Additionally, the Hh signaling pathway appears to interact with HDAC6, and simultaneous inhibition using cyclobenzaprine and Tubastatin A was found to be more effective in reducing GBM cell viability than single agents. This evidence concerns the gene HDAC6 and glioblastoma.